Blood interleukin 10 levels parallel the severity of septic shock.

[1]  J. Reynolds,et al.  Interleukin-10. A role in the development of postoperative immunosuppression. , 1997 .

[2]  P. Parsons,et al.  Circulating IL-1ra and IL-10 levels are increased but do not predict the development of acute respiratory distress syndrome in at-risk patients. , 1997, American journal of respiratory and critical care medicine.

[3]  T. van der Poll,et al.  Effects of IL-10 on systemic inflammatory responses during sublethal primate endotoxemia. , 1997, Journal of immunology.

[4]  S. Ashley,et al.  Interleukin-10 prevents death in lethal necrotizing pancreatitis in mice. , 1996, Surgery.

[5]  A. J. van der Heijden,et al.  Interleukin-10 and soluble tumor necrosis factor receptors in cerebrospinal fluid of children with bacterial meningitis. , 1996, The Journal of infectious diseases.

[6]  T. van der Poll,et al.  Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. , 1996, The Journal of clinical investigation.

[7]  E. Radwanski,et al.  Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. , 1996, Blood.

[8]  J. Vincent,et al.  Corticosteroids increase blood interleukin-10 levels during cardiopulmonary bypass in men. , 1996, Surgery.

[9]  U. Steckholzer,et al.  Interleukin-10 attenuates the release of proinflammatory cytokines but depresses splenocyte functions in murine endotoxemia. , 1996, Archives of surgery.

[10]  T. van der Poll,et al.  Endogenous IL-10 protects mice from death during septic peritonitis. , 1995, Journal of immunology.

[11]  T. Standiford,et al.  Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. , 1995, Journal of immunology.

[12]  A. Eerenberg,et al.  Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing protein. , 1995, The Journal of infectious diseases.

[13]  A. Waage,et al.  High levels of interleukin 10 in serum are associated with fatality in meningococcal disease , 1995, Infection and immunity.

[14]  L. Shapiro,et al.  A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. , 1995, Journal of immunology.

[15]  X. Nuvials,et al.  Interleukin-10 and the monocyte/macrophage-induced inflammatory response in septic shock. , 1995, The Journal of infectious diseases.

[16]  M. Goldman,et al.  High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock. , 1995, The Journal of infectious diseases.

[17]  T. van der Poll,et al.  Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees , 1994, The Journal of experimental medicine.

[18]  P. Quirke,et al.  Role of circumferential margin involvement in the local recurrence of rectal cancer , 1994, The Lancet.

[19]  P. Vandenabeele,et al.  Interleukin‐10 controls interferon‐γ and tumor necrosis factor production during experimental endotoxemia , 1994, European journal of immunology.

[20]  J. Cavaillon,et al.  Circulating interleukin‐8 concentrations in patients with multiple organ failure of septic and nonseptic origin , 1994, Critical care medicine.

[21]  J. Devière,et al.  Interleukin-10 production during septicaemia , 1994, The Lancet.

[22]  C. Wanidworanun,et al.  Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis. , 1993, Journal of immunology.

[23]  G. Constantin,et al.  Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide , 1993, The Journal of experimental medicine.

[24]  T. van der Poll,et al.  Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. , 1993, The Journal of infectious diseases.

[25]  M. Howard,et al.  Interleukin 10 protects mice from lethal endotoxemia , 1993, The Journal of experimental medicine.

[26]  J. Vincent,et al.  Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. , 1993, Chest.

[27]  W. Fiers,et al.  Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia , 1993, The Journal of experimental medicine.

[28]  S. Moncada,et al.  Interleukin-10 (IL-10) inhibits the induction of nitric oxide synthase by interferon-gamma in murine macrophages. , 1992, Biochemical and biophysical research communications.

[29]  T. Mosmann,et al.  IL-10 inhibits cytokine production by activated macrophages. , 1991, Journal of immunology.

[30]  C G Figdor,et al.  Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes , 1991, The Journal of experimental medicine.

[31]  T. Calandra,et al.  High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. , 1991, The American journal of medicine.

[32]  H. Büller,et al.  Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways , 1990 .

[33]  C. Hack,et al.  Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. , 1989, The American journal of medicine.

[34]  C. Sprung,et al.  Complement activation in septic shock patients , 1986, Critical care medicine.

[35]  Germaine Greer,et al.  van Deventer H , 1968 .